These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37114884)

  • 1. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
    Lee YH; Song GG
    Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
    Lee YH; Song GG
    Pharmacogenomics J; 2023 Nov; 23(6):210-216. PubMed ID: 37149714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
    Mahmoud I; Moalla M; Ben Tekaya A; Bouden S; Rouached L; Tekaya R; Saidane O; Gorji Y; Elleuch M; Laatar A; Hamdi W; Abdelmoula L; Sfar I
    Drug Metab Pers Ther; 2023 Jun; 38(2):155-162. PubMed ID: 36919284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Rheumatol Int; 2014 Oct; 34(10):1409-15. PubMed ID: 24728031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.
    Lee YH; Choi SJ; Ji JD; Song GG
    Pharmacogenomics; 2016 Aug; 17(13):1465-77. PubMed ID: 27490376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FCGR2A, FCGR3A, FCGR3B polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2015; 33(5):647-54. PubMed ID: 26314337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
    J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
    Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
    J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis.
    Song GG; Lee YH
    Mol Biol Rep; 2013 Aug; 40(8):4985-93. PubMed ID: 23649770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
    Montes A; Perez-Pampin E; Joven B; Carreira P; Fernández-Nebro A; Del Carmen Ordóñez M; Navarro-Sarabia F; Moreira V; Vasilopoulos Y; Sarafidou T; Caliz R; Ferrer MA; Cañete JD; de la Serna AR; Magallares B; Narváez J; Gómez-Reino JJ; Gonzalez A
    Pharmacogenomics; 2015; 16(4):333-45. PubMed ID: 25823782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
    Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
    Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
    Morgan AW; Barrett JH; Griffiths B; Subramanian D; Robinson JI; Keyte VH; Ali M; Jones EA; Old RW; Ponchel F; Boylston AW; Situnayake RD; Markham AF; Emery P; Isaacs JD
    Arthritis Res Ther; 2006; 8(1):R5. PubMed ID: 16356189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the
    Márquez Pete N; Maldonado Montoro MDM; Pérez Ramírez C; Martínez Martínez F; Martínez de la Plata JE; Daddaoua A; Jiménez Morales A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34207385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between FCGR3A polymorphisms and susceptibility to rheumatoid arthritis: a metaanalysis.
    Lee YH; Ji JD; Song GG
    J Rheumatol; 2008 Nov; 35(11):2129-35. PubMed ID: 18843786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
    Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
    Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
    Kjersem JB; Skovlund E; Ikdahl T; Guren T; Kersten C; Dalsgaard AM; Yilmaz MK; Fokstuen T; Tveit KM; Kure EH
    BMC Cancer; 2014 May; 14():340. PubMed ID: 24884501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
    Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
    Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.